文献速递流行病学与生物统计真实世界研究与卫生经济

常规收集数据用于结局评估的随机试验与传统试验的治疗效应比较:一项元研究

Treatment effects in randomised trials using routinely collected data for outcome assessment versus traditional trials: meta-research study.
PubMed 文献 · BMJ · 2021-03-03

该元研究比较了使用常规收集数据评估结局的随机临床试验(RCD-RCT)与不使用常规收集数据的传统试验的治疗效应估计。纳入84项RCD-RCT和463项传统试验,涵盖22个临床问题。结果显示RCD-RCT的治疗效应估计比传统试验低20%(比值比之比0.80,95%CI 0.70-0.91),提示常规收集数据可能影响治疗效应的评估。

要点

  • 使用常规收集数据评估结局的随机试验治疗效应估计比传统试验低20%。
  • 不同结局类型、数据来源和数据质量亚组结果相似。
  • 该差异对医疗决策和真实世界证据应用可能有影响。

核心结论

  • 使用常规收集数据评估结局的随机临床试验显示的治疗获益小于不使用常规收集数据的传统试验。

研究设计与样本

  • 元研究,比较使用常规收集数据评估结局的随机临床试验与同一Cochrane综述meta分析中的传统试验。
  • 纳入84项RCD-RCT和463项传统试验,涵盖22个临床问题。

主要发现

  • RCD-RCT的治疗效应估计比传统试验低20%(比值比之比0.80,95%CI 0.70-0.91,I2=14%)。
  • 死亡率结局的比值比之比为0.92(95%CI 0.74-1.15,I2=12%)。
  • 非死亡率结局的比值比之比为0.71(95%CI 0.60-0.84,I2=8%)。
  • 电子健康记录数据来源的比值比之比为0.81(95%CI 0.59-1.11,I2=28%)。
  • 登记数据库来源的比值比之比为0.86(95%CI 0.75-0.99,I2=20%)。

关键数值与推荐

  • 纳入标准:使用任何类型常规收集数据(包括登记数据库、电子健康记录和行政数据库)评估结局的随机临床试验,且纳入Cochrane综述的meta分析中,与不使用常规收集数据测量结局的传统试验一起分析。

临床怎么用

  • 临床决策和真实世界证据应用时需考虑常规收集数据评估结局可能低估治疗效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare effect estimates of randomised clinical trials that use routinely collected data (RCD-RCT) for outcome ascertainment with traditional trials not using routinely collected data. DESIGN: Meta-research study. DATA SOURCE: Studies included in the same meta-analysis in a Cochrane review. ELIGIBILITY CRITERIA FOR STUDY SELECTION: Randomised clinical trials using any type of routinely collected data for outcome ascertainment, including from registries, electronic health records, and administrative databases, that were included in a meta-analysis of a Cochrane review on any clinical question and any health outcome together with traditional trials not using routinely collected data for outcome measurement. REVIEW METHODS: Effect estimates from trials using or not using routinely collected data were summarised in random effects meta-analyses. Agreement of (summary) treatment effect estimates from trials using routinely collected data and those not using such data was expressed as the ratio of odds ratios. Subgroup analyses explored effects in trials based on different types of routinely collected data. Two investigators independently assessed the quality of each data source. RESULTS: 84 RCD-RCTs and 463 traditional trials on 22 clinical questions were included. Trials using routinely collected data for outcome ascertainment showed 20% less favourable treatment effect estimates than traditional trials (ratio of odds ratios 0.80, 95% confidence interval 0.70 to 0.91, I2=14%). Results were similar across various types of outcomes (mortality outcomes: 0.92, 0.74 to 1.15, I2=12%; non-mortality outcomes: 0.71, 0.60 to 0.84, I2=8%), data sources (electronic health records: 0.81, 0.59 to 1.11, I2=28%; registries: 0.86, 0.75 to 0.99, I2=20%; administrative data: 0.84, 0.72 to 0.99, I2=0%), and data quality (high data quality: 0.82, 0.72 to 0.93, I2=0%). CONCLUSIONS: Randomised clinical trials using routinely collected data for outcome ascertainment show smaller treatment benefits than traditional trials not using routinely collected data. These differences could have implications for healthcare decision making and the application of real world evidence.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Mc Cord KA, Ewald H, Agarwal A, et al. Treatment effects in randomised trials using routinely collected data for outcome assessment versus traditional trials: meta-research study. BMJ. 2021. PMID: 33658187. doi:10.1136/bmj.n450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。